Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables - Other: 2010-2024

Historic Receivables - Other for China Pharma Holdings (CPHI) over the last 11 years, with Dec 2024 value amounting to $30,286.

  • China Pharma Holdings' Receivables - Other rose 31.62% to $61,275 in Q3 2025 from the same period last year, while for Sep 2025 it was $61,275, marking a year-over-year increase of 31.62%. This contributed to the annual value of $30,286 for FY2024, which is 80.82% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Receivables - Other is $30,286, which was down 80.82% from $157,944 recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Receivables - Other peaked at $1.4 million during FY2021, and registered a low of $29,139 during FY2022.
  • Moreover, its 3-year median value for Receivables - Other was $30,286 (2024), whereas its average is $72,456.
  • Per our database at Business Quant, China Pharma Holdings' Receivables - Other plummeted by 97.96% in 2022 and then skyrocketed by 442.04% in 2023.
  • Over the past 5 years, China Pharma Holdings' Receivables - Other (Yearly) stood at $740,316 in 2020, then surged by 92.50% to $1.4 million in 2021, then plummeted by 97.96% to $29,139 in 2022, then soared by 442.04% to $157,944 in 2023, then slumped by 80.82% to $30,286 in 2024.